Browse > Article
http://dx.doi.org/10.4014/jmb.2110.10029

COVID-19 Drug Development  

Kim, Seungtaek (Zoonotic Virus Laboratory, Institut Pasteur Korea)
Publication Information
Journal of Microbiology and Biotechnology / v.32, no.1, 2022 , pp. 1-5 More about this Journal
Abstract
Diagnostics, vaccines, and drugs are indispensable tools and control measures employed to overcome infectious diseases such as coronavirus disease 2019 (COVID-19). Diagnostic tools based on RT-PCR were developed early in the COVID-19 pandemic and were urgently required for quarantine (testing, tracing and isolation). Vaccines such as mRNA vaccines and virus-vectored vaccines were also successfully developed using new platform technologies within one year after identifying severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as the causative agent of COVID-19. Drug development has been conducted in various ways including drug repurposing, convalescent plasma therapy, and monoclonal antibody development. Among the above efforts, this review examines COVID-19 drug development along with the related and upcoming challenges.
Keywords
COVID-19; SARS-CoV-2; drug repurposing; monoclonal antibody; convalescent plasma;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Urakova N, Kuznetsova V, Crossman DK, Sokratian A, Guthrie DB, Kolykhalov AA, et al. 2018. β-d-N4-Hydroxycytidine is a potent anti-alphavirus compound that induces a high level of mutations in the viral genome. J. Virol. 92: e01965-17.
2 Toots M, Yoon JJ, Cox RM, Hart M, Sticher ZM, Makhsous N, et al. 2019. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci. Transl. Med. 11: eaax5866.   DOI
3 Covid-19 Antiviral Efforts | Pfizer Available online: https://www.pfizer.com/science/coronavirus/antiviral-efforts (Accessed on Oct. 10, 2021).
4 De Clercq E, Li G. 2016. Approved antiviral drugs over the past 50 Years. Clin. Microbiol. Rev. 29: 695-747.   DOI
5 Menachery VD, Yount BL, Debbink K, Agnihothram S, Gralinski LE, Plante JA, et al. 2015. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat. Med. 21: 1508-1513.   DOI
6 Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, Si H-R, et al. 2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579: 270-273.   DOI
7 Ashburn TT, Thor KB. 2004. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 3: 673-683.   DOI
8 Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M, et al. 2020. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. JAMA Netw. Open 3: e208857.   DOI
9 Ko M, Jeon S, Ryu W, Kim S. 2021. Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells. J. Med. Virol. 93: 1403-1408.   DOI
10 Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J, Morris J, et al. 20201. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N. Engl. J. Med. 384: 229-237.
11 Gottlieb RL, Nirula A, Chen P, Boscia J, Heller B, Morris J, et al. 2021. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19. JAMA 325: 632.   DOI
12 Gupta A, Gonzalez-Rojas Y, Juarez E, Casal MC, Moya J, Falci, et al. 2021. Early Covid-19 treatment with SARS-CoV-2 neutralizing antibody sotrovimab. medRxiv 2021.05.27.21257096.
13 Korley FK, Durkalski-Mauldin V, Yeatts SD, Schulman K, Davenport RD, Dumont LJ, et al. 2021. Early convalescent plasma for high-risk outpatients with Covid-19. N. Engl. J. Med. 385: 1951-1960.   DOI
14 Sahu AK, Mathew R, Bhat R, Malhotra C, Nayer J, Aggarwal P, et al. 2021. Steroids use in non-oxygen requiring COVID-19 patients: a systematic review and meta-analysis. QJM 114: 455-463.   DOI
15 RECOVERY Collaborative Group. 2021. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet (London, England) 397: 1637-1645.   DOI
16 Reynard O, Nguyen X-N, Alazard-Dany N, Barateau V, Cimarelli A, Volchkov V. 2015. Identification of a new ribonucleoside inihibitor of Ebola virus replication. Viruses 7: 6233-6240.   DOI
17 Agostini ML, Pruijssers AJ, Chappell JD, Gribble J, Lu X, Andres EL, et al. 2019. Small-molecule antiviral β-D- N 4 -hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance. J. Virol. 93: e01348-19.
18 Track the Coronavirus Outbreak on Johns Hopkins Live Dashboard | MedPage Today Available online: https://www.medpagetoday.com/infectiousdisease/publichealth/84698 (Accessed on Oct. 10, 2021).
19 Hu B, Guo H, Zhou P, Shi Z-L. 2021. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 19: 141-154.   DOI
20 Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. 2020. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181: 271-280.e8.   DOI
21 Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, et al. 2017. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci. Transl. Med. 9: eaal3653.   DOI
22 V'kovski P, Kratzel A, Steiner S, Stalder H, Thiel V. 2021. Coronavirus biology and replication: implications for SARS-CoV-2. Nat. Rev. Microbiol. 19: 155-170.   DOI
23 Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al.2020. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N. Engl. J. Med. 382: 2411-2418.   DOI
24 Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. 2020. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N. Engl. J. Med. 382: 1787-1799.   DOI
25 James H McMahon, Andrew Udy, Anton Y Peleg. 2020. Remdesivir for the treatment of Covid-19- preliminary report. N. Engl. J. Med. 383: 992-993.   DOI
26 Group TRC. 2021. Dexamethasone in hospitalized patients with Covid-19. N. Engl. J. Med. 384: 693-704.   DOI
27 Kumar S, Chandele A, Sharma A. 2021. Current status of therapeutic monoclonal antibodies against SARS-CoV-2. PLoS Pathog. 17: e1009885.   DOI
28 Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore, R, et al. 2021. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N. Engl. J. Med. 384: 238-251.   DOI
29 Merck and Ridgeback's Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study - Merck.com Available online: https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravirreduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-ormoderat/ (Accessed on Oct. 10, 2021).
30 Yamamoto M, Kiso M., Sakai-Tagawa Y, Iwatsuki-Horimoto K, Imai M, Takeda M, et al. 2020. The anticoagulant nafamostat potently inhibits SARS-CoV-2 S protein-mediated fusion in a cell fusion assay system and viral infection in vitro in a cell-type-dependent manner. Viruses 12: 629.   DOI
31 Griffin DO, Brennan-Rieder D, Ngo B, Kory P, Confalonieri M, Shapiro L, et al. 2021. The importance of understanding the stages of COVID-19 in treatment and trials. AIDS Rev. 23: 40-47.
32 WHO Solidarity Trial Consortium, Pan H, Peto R, Henao-Restrepo A-M, Preziosi M-P, Sathiyamoorthy V, et al. 2021. Repurposed antiviral drugs for Covid-19 - interim WHO solidarity trial results. N. Engl. J. Med. 384: 497-511.   DOI
33 Veklury® (Remdesivir) Significantly Reduced Risk of Hospitalization in High-Risk Patients with COVID-19 Available online: https://www.gilead.com/news-and-press/press-room/press-releases/2021/9/veklury-remdesivir-significantly-reduced-risk-ofhospitalization-in-highrisk-patients-with-covid19 (Accessed on Oct. 9, 2021).
34 Hoffmann M, Schroeder S, Kleine-Weber H, Muller MA, Drosten C, Pohlmann S. 2020. Nafamostat mesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19. Antimicrob. Agents Chemother. 64: e00754-20.
35 Marconi VC, Ramanan AV, de Bono S, Kartman CE, Krishnan V, Liao R, et al. 2021. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir. Med. 9: 1407-1418.   DOI
36 Jeon S, Ko M, Lee J, Choi I, Byun SY, Park S, et al. 2020. Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs. Antimicrob. Agents Chemother. 64: e00819-20.